Work at Eikon Therapeutics Inc. has led to the discovery of new ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
Recent patents from Vigil Neuroscience Inc. describe heterocyclic compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2) agonists.
Regulonix LLC and the U.S. Department of Health and Human Services (HHS) have jointly patented new sodium channel protein type 9 subunit α (SCN9A; Nav1.7) blockers reported to be useful for the treatment of neuropathic pain.
Dana Farber Cancer Institute Inc. and Stanford University have patented new molecular glue degraders comprising cereblon (CRBN) binding moiety acting as casein kinase 1 isoform α and/or wee1-like protein kinase (Wee1) degradation inducers reported to be useful for the treatment of cancer.
Researchers from Nikang Therapeutics Inc. and Shanghai Blueray Biopharma Co. Ltd. have discovered GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Eli Lilly & Co. has divulged relaxin receptor 1 (RXFP1; LGR7) agonists reported to be useful for the treatment of diabetes, stroke, atherosclerosis, pulmonary hypertension, chronic obstructive pulmonary disease, hypercholesterolemia, chronic kidney disease and diabetes nephropathy, among others.
Incyte Corp. has described GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer, inflammatory and immunological disorders.
The med tech patent wars opened a new front in the region of screening tests for colorectal cancer, pitting Exact Sciences Corp., of Madison, Wisc., against St. Louis-based Geneoscopy Inc.
Gewu Biotechnology (Jiangsu) Co. Ltd. has described histone-lysine N-methyltransferase EZH1 and/or EZH2 inhibitors reported to be useful for the treatment of cancer, autoimmune diseases, metabolic diseases, and genetic, hematological, neurological, psychiatric and inflammatory disorders.
Neurocrine Biosciences Inc. has divulged cyclic peptides acting as corticotropin-releasing factor 1 and 2 (CRF1 and CRF2) antagonists reported to be useful for the treatment of congenital adrenal hyperplasia, cancer, osteoporosis, myopathy, hyperglycemia, Cushing syndrome, peptic ulcers and hypertension, among others.
RSS
